Moderna-Merck melanoma vaccine cuts death or recurrence 42%
In a phase 3 melanoma trial of more than 1,100 patients, intismeran autogene plus Keytruda cut the risk of death or recurrence by 42%; U.S. filing is pending.
Topic
Phase 3 Clinical Trial
Topic
Phase 3 Clinical Trial
Personalised melanoma vaccine cuts death or recurrence risk by 42%
A phase 3 trial of the personalised mRNA vaccine Intismeran plus Keytruda found a 42% lower risk of death or recurrence in 1,137…